Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma

作者：Puig Josep^*; Blasco Gerard; Essig Marco; Daunis i Estadella Josep; Laguillo Gemma; Quiles Ana Maria; Remollo Sebastian; Bergmann Karsten; Joly Carme; Bernado Lluis; Sanchez Gonzalez Javier; Pedraza Salvador

来源：European Radiology, 2013, 23(4): 1093-1101.

DOI：10.1007/s00330-012-2678-9

• Brain neoplasms
• Glioblastoma
• Magnetic resonance imaging
• Contrast media
• Gadolinium

We qualitatively and quantitatively compared MRI enhancement obtained with gadofosveset, an albumin-binding blood-pool contrast agent, and with gadobutrol, an extracellular contrast agent, in patients with glioblastoma. %26lt;br%26gt;Thirty-five patients (25 men; 64 +/- 14 years) with histologically proven glioblastoma underwent MRI including pre- and post-contrast T1-weighted SE images acquired 5 min after gadobutrol (0.1 mmol/kg) and, 48 h later, images acquired with identical parameters 5 min and 3, 6, and 24 h after gadofosveset (0.03 mmol/kg). Lesion extent, delineation, internal morphology, multifocality, and global diagnostic preference were evaluated quantitatively for the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and contrast enhancement (CE). %26lt;br%26gt;Mean values of SNR, CNR, and tumour CE were highest 6 h after gadofosveset. Multifocality was seen in 17 (48.6 %) patients; additional lesions had stronger enhancement 6 h after gadofosveset in 12 patients (70.6 %). In 21 (60 %) patients, radiologists%26apos; global preference was highest in images acquired 6 h after gadofosveset (kappa = 0.764). In 22 patients (62.8 %), all qualitative endpoints were better at 5 min after gadobutrol than in images acquired 5 min after gadofosveset injection. %26lt;br%26gt;Gadobutrol gives significant tumour enhancement in early postcontrast imaging. However, images acquired 6 h after gadofosveset injection have significantly better diagnostic information endpoints and contrast enhancement. %26lt;br%26gt;aEuro cent We compared MRI enhancement with gadofosveset and gadobutrol in patients with glioblastoma. %26lt;br%26gt;aEuro cent Gadobutrol provides better enhancement in early enhanced imaging at 5 min. %26lt;br%26gt;aEuro cent Gadofosveset at 6 h post-injection provides optimal enhancement and diagnostic information endpoints. %26lt;br%26gt;aEuro cent Gadofosveset is feasible for diagnostic quality contrast-enhanced MRI in glioblastoma. %26lt;br%26gt;aEuro cent The contrast medium dose can be reduced without disminishing the image quality using gadofosveset.

• 出版日期2013-4